Kumiai Chemical Industry Co., Ltd.
【Kumiai Chemical】Revision of Earnings Guidance for the First Half of 2026 | Sales of ¥102.9 billion (+10.9%)
Kumiai Chemical announced a significant upward revision of its consolidated earnings forecast for the second quarter of the fiscal year ending October 2026, projecting sales of ¥102.9 billion (+10.9% YoY), operating profit of ¥10.4 billion (+70.5%), and net income attributable to owners of the parent of ¥8.7 billion (+97.7%).
Key Figures
- Sales: ¥102.9 billion (+10.9% vs. previous forecast)
- Operating profit: ¥10 billion (+70.5%)
- Net income attributable to owners of the parent: ¥8.7 billion (+97.7%)
AI要約
Overview of Business Performance
Kumiai Chemical has significantly upwardly revised its consolidated earnings forecast for the second quarter of the fiscal year ending October 2026. The company now projects sales of ¥102.9 billion (+10.9% compared to the previous forecast), operating profit of ¥10.4 billion (+70.5%), ordinary income of ¥13.7 billion (+67.1%), and net income attributable to owners of the parent of ¥8.7 billion (+97.7%). This increase is mainly due to accelerated shipments in the pesticides and agricultural-related business segments, driven by sales promotions ahead of the entry of generic products of Axive into the U.S. market, as well as strong performance in the chemical products business. The full-year earnings estimates remain unchanged, considering the impact of the Middle East situation.
Outlook and Impact
While future trends in business performance may warrant revisions, the company currently maintains its original full-year forecast. It anticipates recording impairment losses and restructuring costs as extraordinary losses, aiming for further improvement and stable business progression. The company will continue proactive sales promotion and cost management, considering the possibility that prolonged geopolitical issues in the Middle East may impact its operations.
Kumiai Chemical Industry Co., Ltd.
Company overview · Stock price · Financial data · All IR